Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-23
2010-10-12
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C540S456000
Reexamination Certificate
active
07812032
ABSTRACT:
A rapamycin analog composition includes a crystalline form of a rapamycin analog. The crystal can be a hydrate, dehydrate, solvate, or desolvate. The rapamycin analog can have a structure of Formula 1, which is optionally a prodrug, salt, derivative, or combination thereof:
REFERENCES:
patent: 6015815 (2000-01-01), Mollison
patent: 2003/0129215 (2003-07-01), Mollison et al.
patent: 2008/0091008 (2008-04-01), Viswanath et al.
patent: WO 99/15530 (1999-04-01), None
patent: 2006/023627 (2006-03-01), None
patent: 2006/060616 (2006-06-01), None
patent: WO 2008/014222 (2008-01-01), None
Wagner et al, “Rapamycin Analogs With Reduced Systemic Exposure” Bioorganic & Medicinal Chemistry Letters 2005.
Pagano, Thomas G. “Spectral Assignments and Reference Data”, Magnetic Resonance in Chemistry, Dec. 13, 2004.
European Search Reprot for 07799771.6, mailed Sep. 23, 2009, 7 pgs.
Bartelt Larry
Borchardt Thomas
Chen Shuang
Dhaon Madhup
Henry Rodger
Abbott Laboratories
Kifle Bruck
Squire Sanders & Dempsey LLP
LandOfFree
Crystalline forms of rapamycin analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline forms of rapamycin analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline forms of rapamycin analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4192108